Overview
To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
Status:
Recruiting
Recruiting
Trial end date:
2022-02-15
2022-02-15
Target enrollment:
0
0
Participant gender:
All
All
Summary
To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Ocular Therapeutix, Inc.
Criteria
Inclusion Criteria:- Dry Eye Disease diagnosis
- VAS eye dryness severity score ≥ 40.
Exclusion Criteria:
- Are unwilling to discontinue use of contact lenses
- Are unwilling to withhold use of artificial tears.